Results 121 to 130 of about 5,496 (285)

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Oferta y demanda de marihuana medicinal en Colombia : ¿existe una oportunidad de mercado?

, 2019
En el siguiente trabajo se presenta el comportamiento de la oferta y la demanda de la marihuana medicinal en Colombia visto desde la perspectiva tanto de expertos y conocedores del tema como de consumidores y futuros compradores. Así mismo, se demuestra la existencia de una oportunidad de negocio atractiva para quienes deseen invertir en este sector ...
Lombana Bedoya, Tomás, Hadad Canizales, Marianna, Arévalo Castaño, Santiago Alejandro   +2 more
openaire   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Marihuana controversia legal, con fin medicinal

, 2018
Artículo de ...
openaire   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Psychedelics to Relieve Psychological Suffering Associated with a Life-Threatening Diagnosis: Time for a Canadian Policy Discussion. [PDF]

Healthc Policy, 2023
Kratina S, Lo C, Strike C, Schwartz R, Rush B.   +4 more
europepmc   +1 more source

Does the total consumption model apply to cannabis use?

Addiction, EarlyView.
Abstract Aims To test whether the total consumption model and its extension, the theory of collectivity, apply to adolescent cannabis use. We estimated: (1) whether the distribution of cannabis use frequency was stable over time; (2) whether changes in average cannabis use were mirrored across consumption quantiles; and (3) whether higher average use ...
Thor Norström, Håkan Leifman
wiley   +1 more source

Uso de cannabis en el tratamiento de pacientes con diabetes

Gaceta Médica Estudiantil
Introducción: la diabetes, una condición metabólica persistente, afecta órganos vitales. El cannabis, con sus cannabinoides como el tetrahidrocannabinol  y el cannabidiol, ha ganado interés medicinal en pacientes con esta enfermedad. Objetivo: describir
Pablo Martin Hinostroza-Medina , Olivia Altamirano-Guerrero, Karina Alexandra Arguello-Ramos   +2 more
doaj  

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source